Very-high-dose phenobarbital for refractory status epilepticus in children

Thomas O. Crawford, Wendy G. Mitchell, Lawrence S. Fishman, S. Robert Snodgrass

Research output: Contribution to journalArticlepeer-review

Abstract

Status epilepticus refractory to initial anticonvulsant therapy is a serious condition with a high morbidity and mortality. We present 50 cases with refractory status epilepticus (RSE) treated with very-high-dose phenobarbital (VHDPB) without reference to a predetermined maximum level or dose. Maximum serum levels ranged from 70 to 344 μg/d (median, 114 μg/ml). VHDPB controlled seizures in all cases where no limits were imposed upon maximum dose (47/50). We found no maximum dose beyond which further doses are likely to be ineffective. Forty patients were intubated prior to VHDPB, but recovered respiratory drive and could be removed from the ventilator despite very high serum levels. This is explained by acute drug tolerance. Hypotension was unusual, related to the highest levels, and easily controlled. VHDPB has many relative advantages over other therapies presently used for RSE.

Original languageEnglish (US)
Pages (from-to)1035-1040
Number of pages6
JournalNeurology
Volume38
Issue number7
StatePublished - Jul 1988
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Very-high-dose phenobarbital for refractory status epilepticus in children'. Together they form a unique fingerprint.

Cite this